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Carboxylic acid reductase (CAR) catalyzes the ATP- and NADPH-dependent 
reduction of carboxylic acids to the corresponding aldehydes. The enzyme is 
related to the non-ribosomal peptide synthetases, consisting of an adenylation 
domain fused via a peptidyl carrier protein (PCP) to a reductase termination 
domain. Crystal structures of the CAR adenylation–PCP didomain demonstrate 
that large-scale domain motions occur between the adenylation and thiolation 
states. Crystal structures of the PCP–reductase didomain reveal that 
phosphopantetheine binding alters the orientation of a key Asp, resulting in a 
productive orientation of the bound nicotinamide. This ensures that reduction of 
the aldehyde product does not occur. Combining crystallography with small-angle 
x-ray scattering (SAXS), we propose that molecular interactions between 
initiation and termination domains are limited to competing PCP docking sites. 
This is supported by the fact that (R)-pantetheine can support CAR activity for 
mixtures of the isolated domains. Our model suggests directions for further 
development of CAR as a biocatalyst. 
 
Introduction 
 
The ATP- and NADPH-dependent reduction of carboxylic acids to the corresponding 
aldehydes is catalyzed by the bacterial carboxylic acid reductase (CAR) enzymes [1-3]. 
These enzymes consists of an adenylation domain fused via a peptidyl carrier protein 
(PCP) to a reductase termination domain, and are related to the nonribosomal peptide 
synthetases (NRPS) [4-7]. CAR enzymes show substantial promise as green biocatalysts 
for the conversion of aromatic and short chain carboxylic acids into the corresponding 
aldehydes [3]. Individual CARs have been shown to convert a wide range of substrates, 
featuring in applications that range from the conversion of long-chain fatty acids into 
fuel precursors [8-12], to the production of starting materials for cascade reactions that 
generate enantiomerically pure chiral building blocks [13] (Supplementary Results, 
Supplementary Fig. 1). Newly characterized CAR family members continue to expand 
this synthetic chemistry toolbox [14]. However, unlocking the catalytic potential of these 
enzymes is hampered by the lack of mechanistic and structural insights. CAR represents 
a distant relation of the NRPS family, lacking any extension module (Fig. 1a). In fact, 
CAR consists of a substrate-activating adenylation domain more closely related in 
substrate specificity and sequence to the acyl-CoA synthetase members of the ANL 
superfamily of adenylating enzymes [15]. While the latter enzymes generate CoA 
thioester products, the CAR adenylation domain is fused to a PCP domain, and thus 
resembles the NRPS initiator (or adenylation) module with respect to the thioester 
product. The similarity with the modular NRPS enzymes extends to the inclusion of a 
terminator domain in CAR: an aldehyde-product-releasing reductase domain is fused to 
the acyl-intermediate carrier PCP. While sequence similarity of the CAR adenylation 
domain with known structures is limited to ~20%, closely related reductase structures 
(~50 % similarity to CAR) from NRPS enzymes are available [16,17]. However, these 
enzymes catalyze the progressive 4-electron reduction of the PCP-bound acyl group to 
the corresponding alcohol. In contrast, CAR catalyzes a strictly 2-electron reduction, 
releasing the corresponding aldehyde product (Fig. 1a).  
 
To provide detailed understanding of the CAR mechanism, we determined the crystal 
structure of individual CAR domains, both with and without the PCP domain. A range of 
CARs was screened for crystallization, and structural data could be obtained for 
enzymes from Nocardia iowensis, Mycobacterium marinum and Segniliparus rugosus. 
Combining the crystallographic structures with SAXS studies, we reveal that large-scale 
domain dynamics underpin catalysis in CAR. Furthermore, we reveal that docking of the 
phosphopantetheine group in the reductase active site leads to reorientation of the 
nicotinamide moiety of bound NADPH from a non-catalytic to a catalytically competent 
position. We propose that this ensures reduction does not proceed beyond the aldehyde 
product, and show that mutagenesis of a single Asp residue involved in the nicotinamide 
reorientation leads to modest formation of the 4-electron-reduced alcohol product.    
 
Results  
 
Structure of and substrate binding by the CAR A domain  
To understand the key determinants underpinning substrate specificity and the 
mechanism of acyl-AMP formation, we determined the structure of the adenylation 
domains (A domains) of CAR from Nocardia iowensis (CARni) and Segniliparus rugosus 
(CARsr). In each case, the structure was obtained in complex with AMP that remained 
tightly bound during purification (Fig. 1b). The AMP is bound at the A domain center, 
establishing an extensive network of molecular contacts conserved across the ANL 
superfamily [15,18]. Most similar structures include the bacterial benzoate-CoA ligase 
[19] and the human medium-chain acyl-coenzyme A synthetase ACSM2A [20] 
(Supplementary Fig. 2a). Previous studies on these enzymes and other members of the 
ANL superfamily have revealed the presence of a mobile C-terminal domain (Asub, 
residues 527-654) that adopts distinct positions correlated to the specific reactions 
catalyzed. Domain motion has been inferred from structures with distinct nucleotide 
ligands, with the ATP-bound form representing the adenylation state of the enzyme, and 
AMP or AMP-acyl bound forms frequently observed bound to the thiolation state [15]. 
For both CAR A domain structures, the exact orientation of the Asub domain is highly 
similar and, despite containing AMP, is more akin to ANL structures that correspond to 
the adenylation state. The universally conserved Lys from ANL motif A10 [18] in the Asub 
domain (K629 in CARsr) makes contact with the nucleotide ligand (a hallmark of the 
adenylation state), while the conserved A8 Gly [18] (located close to the AMP-acyl 
substrate in the thiolation state; G532 in CARsr) is directed away from the active site 
(Supplementary Fig. 2a). The P-loop that grips the terminal ATP phosphates is 
disordered in CARsr while adopting a position wedged in between the Acore (residues 1-
526) and the Asub domains in CARni. In both CAR A domain structures, the domain 
interface established between Asub and the N-terminal Acore domain is more extensive 
when compared with other ANL enzymes in the adenylation state. This suggests the 
conformational equilibrium of the isolated CAR Asub domain remains poised towards the 
adenylation state, apparently unaffected by the nature of the nucleotide ligand. 
 
The acid substrate binding site is identified by benzoic acid bound to CARni and an 
unidentified molecule (modeled as fumarate) present close to the AMP phosphate that 
was co-purified with CARsr (Fig. 1c). Most of the relatively narrow substrate binding 
pocket is lined by hydrophobic residues, with His300 (conserved in CAR enzymes; H315 
in CARsr) located close to both AMP phosphate and the substrate carboxylate. The active 
site volume of CARsr is smaller due to the presence of Phe294 (Ser280 in CARni), and 
distinct in shape due to insertion of Ala425 in CARni. The substrate specificity of these 
enzymes was determined by screening against a diverse carboxylic acid substrate panel 
including benzoic, heterocyclic, phenylacetic/propanoic and fatty acid substrates 
(Supplementary Fig. 1). Para- and meta- substituted benzoic acids, such as toluic acid, 
show high levels of activity against several CAR enzymes. All CARs tested exhibited a 
poor tolerance for ortho- substituents, presumably due to steric hindrance.  
 
The CAR A–PCP didomain is a dynamic entity 
To explore whether the Asub conformation is affected by the presence of the PCP domain, 
and establish how the thioester linkage between the acyl-AMP and the PCP 
phosphopantetheine is formed, we determined the structure of the CARsr adenylation–
PCP region (A–PCP). The latter could be crystallized in two distinct conformations that 
differ in the position of the Asub and PCP domains. While one Asub domain conformation 
is similar to that previously observed for the single A domain (i.e. the adenylation state; 
Fig. 2a,b), a second, distinct conformation was observed in a different crystal form (Fig. 
2c,d). In the adenylation state, the PCP domain is positioned distant from the A domain, 
the Asub–PCP linker region adopting an extended alpha-helical conformation. The PCP 
Ser702 that serves as the phosphopantetheine attachment site is positioned 52 Å away 
from the bound AMP phosphate. In contrast, the relative orientation of both PCP and 
Asub domains has altered in the second A–PCP crystal structure, with the Ser702–AMP 
phosphate distance dramatically shortened to 19 Å. This large reduction in distance is 
the cumulative effect of two distinct domain re-orientations. The adenylation Asub 
domain has reoriented via a rotation of ~165 degrees at the A8–Lys528 hinge region, 
although the Asub center of gravity remains largely in place. Both the position of the 
hinge and extent of rotation resemble the motion seen between the adenylation and 
thiolation conformations in other ANL family members [5,6,15](Fig. 2; Supplementary 
Fig. 2b). The relative orientation of the PCP domain and the Asub domain has also 
changed, with an additional ~75 degree rotation at Ala651 leading to the more dramatic 
PCP domain reorientation. The cumulative effect of both the Lys528 and Ala651 
rotations is a displacement for the PCP domain center of gravity by ~50 Å. The 
reorientation of both PCP and Asub domains leads to a structure compatible with 
thiolation (Fig. 2d). Although phosphopantetheine is not present in our structure, an 
overlay with the related initiation module of NPRS LgrA [7] reveals a very similar 
orientation of the PCP relative to the Acore domain, with the phosphopantetheine linker 
accommodated by a narrow channel lined with conserved consensus sequence elements 
from the Asub domain (Supplementary Fig. 2b).  
 
In addition to the altered Asub–Acore domain interaction of the thiolation conformation, a 
new domain interaction surface is established between the PCP domain and the Acore 
domain, overlapping in part with the adenylation Asub–Acore domain interaction 
(Supplementary Fig. 3). The presence of this additional interaction is therefore likely 
to affect the adenylation–thiolation conformational equilibrium of the Asub domain when 
comparing the isolated A domain with the A-PCP didomain region. Biophysical 
parameters for the CARsr A-PCP in solution were determined by SAXS, multi-angle light 
scattering (MALS) and area under the curve (AUC) analysis (Supplementary Fig. 4). 
Neither of the crystal structures obtained correlated well with the experimental data. 
Rigid-body modeling using both linker regions (K528 and A651) resulted in an 
ensemble of two models that accounted for the SAXS profile, one resembling the A–PCP 
thiolation state crystal structure and the other corresponding to an open conformation 
of the Asub domain not observed in the crystal structures. These data are consistent with 
the expected flexibility of the A–PCP didomain. While the observed position of the PCP 
domain in the adenylation state is influenced by crystal lattice contacts (a total of ten 
putative hydrogen bonding interactions can be observed between the PCP domain and 
symmetry-related monomers), the conformation seen in the crystal structure is likely 
one of a wider range of possible conformations the A–PCP didomain can adopt in 
solution.  
 
CAR R domain structures reveal an on-off equilibrium 
We sought to complement our understanding of the CAR A–PCP didomain by 
determining the structure of the CAR reductase (R) domain. In particular, we wanted to 
determine how this domain ensures that further reduction of the aldehyde product does 
not occur. Crystal structures of the reductase domains from CARsr and CARmm 
(Mycobacterium marinum) reveal that this region is highly similar in structure to the 
terminal reductase domains of other NPRS [16,17], albeit with a distinct orientation of 
the smaller substrate binding domain (Fig. 3a). Furthermore, crystals could be readily 
obtained in a variety of crystal forms. For CARmm, these reveal that two distinct 
conformations of Asp984 (Asp998 in CARsr) in the reductase active site can occur, 
corresponding to active and inactive forms of the reductase, respectively (Fig. 3b). In 
the active form, the nicotinamide moiety is ordered and placed adjacent to conserved 
residues Thr921 and Tyr956. The latter are proposed to form the oxyanion hole that 
assists in reduction of the thioester [21]. Asp984 is positioned pointing away from the 
nicotinamide, buried within the protein matrix and hydrogen bonding to Asp1034. This 
conformation is similar to that observed for the 4-electron reductase from MxaA [17] 
(Supplementary Fig. 5). In contrast, Asp984 adopts a distinct conformation in the 
majority of the CARmm reductase monomers (similar to the Asp998 conformation 
observed for CARsr reductase), leading to a disordered nicotinamide moiety and thus 
inactive state. This disorder is a consequence of the fact that Asp984 and the Ser983 
carbonyl group are located within the nicotinamide binding pocket. The motion of 
Asp984 between both conformations is concomitant with reorientation of the backbone 
of residues 983–985. Comparison of the various CARmm reductase structures reveals 
that the latter appears to be linked to the position of the smaller substrate binding 
domain. This suggests a possible means by which CAR ensures reduction does not 
proceed beyond the aldehyde product: binding of the substrate-thioester PCP affects the 
position of the substrate binding domain, and hence the conformational equilibrium of 
Asp984. The latter appears poised towards the inactive state in the absence of the PCP-
acyl substrate. In contrast, the aldehyde product might lack sufficient binding affinity to 
affect this equilibrium. Recently studied polyketide synthase (PKS) enzymes containing 
reductase off-loading domains implicated in aldehyde (as opposed to alcohol) 
production also contain an Asp residue at the corresponding position [22,23]. However, 
one of these does further reduce the aldehyde product to alcohol in the absence of a 
suitable transaminase to the trap the transient aldehyde intermediate [22]. The 
conformational equilibrium between on- and off-state in the CAR R domain extends 
beyond Asp984 reorganization, including the backbone reorientation of residues 983–
985. Hence, the presence of an Asp984-equivalent residue might not in itself be 
sufficient to determine the product scope. In the case of CARsr, while mutation of the 
equivalent Asp998 to Gly does not appear to affect benzoic acid reduction rates, it does 
lead to formation of the modest levels of the alcohol product in vitro (Supplementary 
Fig. 6).  Furthermore, in contrast to the WT CAR, the CARsr D998G variant displays 
modest benzaldehyde reductase activity. This suggests that Asp998 is required to 
ensure strict 2-electron reductase activity by CAR, and that the R domain has little 
affinity for the isolated benzaldehyde (as opposed to the covalently linked benzoyl-
phosphopantetheine moiety). The physiological substrate(s) of CAR is unknown, and it 
is possible that Asp998 is required to ensure 4-electron reduction does not occur for the 
corresponding aldehydes.  
 
A phosphopantetheine binding-induced activation mechanism 
In order to verify our hypothesis, we determined the crystal structure of the CARsr PCP–
reductase (PCP–R) didomain. As observed for the isolated reductase domains, crystals 
could be readily obtained in the presence of NADPH, and a variety of crystal forms could 
be obtained. The PCP domain is clearly visible in the corresponding crystal structures, 
and adopts a conformation independent of crystal packing, presenting the first crystal 
structure for an intact PCP–R didomain (Fig. 3c). The PCP domain is docked onto the 
larger NADPH binding domain, directly above the ribose 2’-phosphate binding pocket, 
with no direct contacts established to the smaller substrate binding domain. This 
suggests that binding of the adenosine 2’5’-diphosphate moiety of NADPH is likely to 
precede PCP docking, with reorganization of the nicotinamide group linked to 
phosphopantetheine binding. The PCP phosphopantetheine linker Ser702 is located 16 
Å from the nicotinamide binding pocket. In the unmodified CARsr PCP–R structure, the 
bound NADPH nicotinamide remains disordered with Asp984 observed in the inactive 
conformation. In contrast, the crystal structure of the CARsr PCP–R modified with 
phosphopantetheine reveals an active conformation (Fig. 3d,e). In the latter, the smaller 
substrate binding domain has reoriented slightly to establish contacts between the 
phoshopantetheine group and the P1013–Q1015 region, in turn leading to reorientation 
of the Y966 loop region from the larger NADPH-binding domain with concomitant active 
site closure. A plausible model for the reductase acyl-PCP complex is made by extending 
the phosphopantetheine arm with a benzoyl moiety. This directly places the substrate 
acyl group above the pro-S H on the C4 nicotinamide, in agreement with observed 
kinetic isotope effects (KIE; Supplementary Figs. 5 and 9a,b). It also reveals that few, if 
any, interactions are made between the R domain and the benzoyl moiety. The ~50-fold 
decrease in NADPH oxidation levels upon providing benzoyl-CoA as a substrate instead 
of benzoic acid and ATP (i.e. bypassing the A domain) reveals that the increase in 
effective concentration of the thioester substrate by covalent tethering is an important 
factor in achieving high enzyme activity (Table 1). However, no activity could be 
observed with thiobenzoic acid, confirming that thioester substrate affinity is largely 
dependent on the phosphopantetheine linker region as opposed to the benzoyl moiety.  
This also provides a likely explanation for the modest reductase activity observed with 
benzaldehyde in the case of the CARsr D998G variant. In addition, the free 
phosphopantetheine thiol group itself represents a steric hindrance to aldehyde binding 
directly above the nicotinamide. The latter is demonstrated both by the fact that the apo 
form of CARsr D998G (i.e. unmodified with phosphopantetheine) displays higher 
benzaldehyde reduction activity compared to the holo CARsr D998G, and by the fact the 
presence of free phosphopantetheine inhibits benzaldehyde reduction observed for 
either of these variants (Table 1). 
 
Mutation of residues involved in establishing contacts between the R domain and the 
phoshopantetheine group abolish CAR activity (Supplementary Fig. 5d). This strongly 
suggests the presence of the substrate-phosphopantetheine itself is required to induce 
Asp 984–Ser 985 reorientation and concomitant reductase activation. This is supported 
by the fact that benzoyl-CoA can act as a substrate for the isolated CARsr R domain and 
R–PCP didomain. To prove that the (R)-pantetheine moiety itself is required for 
activation of the R domain, we tested for benzoic acid reductase activity of a CARsr 
S702A mutant in the presence of (R)-pantetheine or a similarly sized thiol. Only the 
addition of (R)-pantetheine was able to rescue CAR activity for the S702A variant, 
confirming that free (R)-pantetheine can bypass the lack of PCP Ser702-bound 
phosphopantetheine group for the A domain, resulting in formation of a benzoyl-
pantetheine thioester that can serve as a substrate for the R domain. Biophysical 
parameters for the unmodified CARsr PCP–R didomain in solution were determined by 
SAXS, MALS and AUC analysis, revealing that neither of the crystal structures obtained 
correlate well with the experimental data (Supplementary Fig. 7). Rigid-body modeling 
using S744 as a linker region revealed that an ensemble of multiple PCP–R 
conformations accounted for the SAXS profile obtained. This suggests a highly dynamic 
nature of the PCP domain in solution, in accordance with the relatively small interaction 
surface observed in the PCP–R crystal structure.  
 
Modeling of the full-length CAR reveals a dynamic entity 
Armed with the various crystal structures of the distinct CARsr PCP-containing regions, 
we modeled the full-length CAR (Fig. 4). While the A–PCP structure in the thiolation 
mode is clearly incompatible with the available PCP–R structures (the PCP cannot be 
simultaneously docked to both the respective partner domains), an overlay of the 
adenylation A–PCP conformation (i.e. PCP-off) with the modified PCP–R (i.e. PCP-on) 
reveals only minor clashes occur between the adenylation and reductase domains (Fig. 
4a). The latter are easily avoided by minimal reorientation of the Asub–PCP Ala651 hinge 
region. An overlay of the thiolation state A–PCP structure with the PCP–R SAXS-derived 
models reveals a very distinct model for the full-length enzyme (Fig. 4b).   
 
To verify the dynamic nature of CAR, we determined the solution structure of CARsr 
using SAXS (Supplementary Fig. 8). Neither of the models presented in Figure 4a,b 
account for the observed SAXS profile, and rigid-body modeling using four domains 
linked by the three identified hinge regions (K528, A651 and S744) reveals that two 
distinct conformations, both representing an open conformation of the enzyme, can 
account for the observed profile (Fig. 4c; Supplementary Fig. 8). The addition of ATP 
and/or NADPH4 (a reduced version of NADPH) did not substantially alter the scattering 
behavior of the sample. This therefore suggests that the dynamic equilibrium between 
the various conformations of the full-length enzyme is not poised towards either the 
adenylation/reduction or thiolation conformations, but likely randomly explores 
various conformations, some relevant with respect to catalysis, others for ligand 
exchange. Substantial solvent viscosity effects on CAR catalytic efficiency support this 
hypothesis (Supplementary Fig. 9c,d). 
 
Domain-exchanged CARs retain activity 
While mixtures of isolated CAR domains do not display benzoic acid reductase activity, 
the addition of free (R)-pantetheine can support CAR activity in such mixtures (Table 
1). This confirms that neither covalent linkage between individual domains nor the 
presence of a PCP domain is an absolute prerequisite for activity. Hence, this suggests 
CAR enzyme activity is not inextricably linked to the exact nature of the covalent linkage 
between the individual CAR domains nor to the respective interdomain surface contacts. 
Hence, this robust dynamic nature of CAR suggests that domain exchange to produce 
novel hybrid CARs should be feasible. Similar domain-exchange experiments carried out 
on NPRS systems have met with some success [24-27]. To test our hypothesis we 
exchanged domains from CARni and CARmm to create nmCAR and mnCAR hybrids. 
Interestingly, both hybrids showed activity towards a range of diverse substrates 
(Supplementary Fig. 10). Further studies will be required to determine the extent by 
which the respective A and R domains determine substrate specificity, but our present 
data suggests that the A domain is the key determinant.  
 
Discussion 
The reduction of carboxylic acids to the corresponding aldehydes is a relatively simple 
reaction, but often suffers from the inadvertent production of alcohol by-products 
through further reduction of the aldehyde product under the conditions used. The 
bacterial carboxylic acid reductase is able to catalyze the strictly 2-electron reduction of 
a range of carboxylic acids using ATP and NADPH. CAR enzymes offer tremendous 
potential for future applications in organic synthesis, particularly with respect to 
generating aldehydes from carboxylic acids under mild reaction conditions. Moreover, 
as recently demonstrated [13], CARs can be combined with other enzymes (e.g. 
transaminases, imine reductases) in cascade processes, thereby enabling the conversion 
of simple, inexpensive starting materials to products with greater functionality and 
complexity. Such cascades will increasingly require engineered CARs with broad 
substrate scope and activity for the synthesis of a wide range of target molecules. 
 
Our crystallographic and solution characterization of CAR suggests an intricate 
mechanism that ensures reduction of the carboxylic acid substrate is restricted to the 
aldehyde level. Crystal structures of the isolated reductase domain reveal two distinct 
conformations of the active site region, only one of which appears catalytically 
competent (i.e. the “on” state) by virtue of the fact the nicotinamide moiety is in close 
proximity to the conserved Thr and Tyr involved in catalysis. However, the latter is only 
apparent in small subset of the available reductase domain monomer structures, with 
the majority adopting an “off” state that has a disordered nicotinamide binding mode. 
The on–off conformational equilibrium thus appears poised towards the off-state for the 
isolated reductase domain, and is largely centered around the reorientation of a key Asp 
residue located close to the nicotinamide. Substrate binding, which in this case can be 
considered to be the acyl-phosphopantetheine-PCP domain, can affect this equilibrium, 
leading to substrate-induced enzyme activation. The latter has been observed in a wide 
range of enzymes, and often forms an integral part of those systems that contain 
inherently dangerous activities from the cellular perspective (i.e. proteases [28], kinases 
[29], and NAD+-dependent ADP-ribosyltransferases [30]). Substrate-induced active site 
remodeling offers a suitable safeguard in such cases.  
 
In the case of CAR, the structures of the PCP–R didomain in the presence and absence of 
the phosphopantetheine modification reveal that active site remodeling occurs as a 
direct consequence of an induced-fit phosphopantetheine docking in the reductase 
active site cleft and not the PCP-domain itself. This is supported by the fact that benzoyl-
CoA can act as a substrate. Although the CAR R domain key Asp that is affected in 
position by the induced fit of the pantetheine moiety is present in other terminal 
reductase domains [22,23], it remains unclear whether this represents a more general 
mechanism to control reduction activity.  
 
In contrast to the intricate activation of the reductase domain, the communication and 
transfer of the activated acyl group appears to depend on a relatively simple and robust 
system consisting of a beads-on-a-string type of arrangement (Fig. 5). The overlay of the 
adenylation A–PCP conformation with the modified PCP–R structure presents a putative 
model for the full-length CARsr structure when in the adenylation/reduction 
conformation (Fig. 4a). This also suggests that reduction of the substrate-
phosphopantetheine linkage might occur simultaneously with activation of the next 
substrate molecule in the adenylation domain, although a scenario whereby these 
reactions occur sequentially [6] remains equally likely. A putative model for the 
thiolation state of the full-length CAR is assembled by combining the thiolation A–PCP 
crystal structure (i.e. PCP-on) with the PCP–R SAXS models (i.e. PCP-off, Fig. 4b). This 
reveals that a dramatic reorientation of the reductase domain with respect to the 
adenylation is required for the transition from the adenylation/reduction conformation 
to the thiolation conformation. Crucially, a comparison of both models clearly suggests 
the absence of a long-lived interaction between the CAR terminal domains. The SAXS 
models of the full length enzyme present a dynamic picture with the various domains 
sampling the conformational space available (Fig. 4c). Hence, the enzyme appears to 
function as a highly mobile entity that makes use of competing docking sites for the PCP 
domain on the Acore and reductase domains. This is consistent with the lack of ATP- and 
benzoic acid-dependent NADPH consumption activity when adding either CAR A domain 
with the cognate PCP–R fragments (Table 1). The lack of interactions and/or 
sophisticated communication between the CAR terminal domains suggests that the CAR 
catalytic repertoire can be diversified by domain exchange with the CAR family as we 
demonstrate here. A similarly robust design was recently uncovered for intermodular 
communication in hybrid PKS–NRPS [31], underpinning the engineering of polyketide-
nonribosomal peptide interfaces [32]. By analogy, this suggests the possibility to explore 
new chemistry by fusion of CAR domains with appropriate NRPS components in future. 
The fact that free (R)-pantetheine can be used to support the activity of isolated 
domains suggests it might even be possible to bypass the need for covalent linkage 
between these components. It also confirms that the A domain can catalyze ATP-
dependent formation of acyl-pantetheine in the absence of the PCP domain, reminiscent 
of the related acyl-CoA ligase activity [19]. Hence, while the isolated A and R domain are 
functional in the presence of (R)-pantetheine, the increase in effective concentration 
arising from covalent tethering to the PCP domain is a substantial contributor to the 
efficiency of the natural system.  
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Substrates 
added, in 
addition to 
ATP and 
NADPH 
Full-
length 
CAR 
CAR 
S702A 
Apo-CAR 
D998G 
CAR 
D998G 
R domain PCP–R 
didomain 
A + 
PCP–R 
didomain 
benzoic acid 278  7 <0.001 <0.001 255  9 <0.001 <0.001 <0.001 
benzoyl-CoA 11  2 3.1  
0.4 
4.3  1.6 9.4  1.0 1.3  1.0 2.5  0.2 1.4  1.2 
benzoyl-CoA + 
(R)-
pantetheine 
ND ND 2.7  0.4 6.9  0.7 ND ND ND 
thiobenzoate <0.001 <0.001 ND ND <0.001 <0.001 <0.001 
benzaldehyde <0.001 <0.001 0.15  
0.05 
0.03  
0.02 
ND ND ND 
benzaldehyde 
+ 
(R)-
pantetheine 
ND ND <0.001 <0.001 ND ND ND 
benzoic acid + 
(R)-
pantetheine 
261  4 6.8  
0.1  
ND ND <0.001 <0.001 3.0  0.8 
benzoic acid + 
decanethiol 
281  
11 
<0.001 ND ND <0.001 <0.001 <0.001 
benzoic acid + 
pentanethiol 
238  3 <0.001 ND ND <0.001 <0.001 <0.001 
ND = not determined 
 
Table 1. Substrate-dependent NADPH oxidation rates (min-1) for CARsr WT and 
variants. A range of substrates (with or without the presence of a thiol compound) 
were incubated with CARsr, NADPH and ATP. Substrate NAPDH oxidation rates were 
highest for the WT enzyme with benzoic acid, but modest activity could be observed for 
both full-length and individual CAR domains when using benzoyl-CoA or in the presence 
of (R)-pantetheine.  
 
 
  
Figure legends 
 
Fig. 1. Carboxylic acid reductase is a modular enzyme. (a) Schematic overview of the 
CAR primary sequence, color coded according to individual domains. A general reaction 
as catalyzed by CAR is shown directly above. Various CAR fragments generated here are 
indicated by arrows. (b) An overlay of the CARsr and CARni A domain crystal structures, 
color coded as in a. (c) A side-by-side comparison of the CARni and CARsr A domain 
substrate-binding regions. 
 
Fig. 2. Structure of the CARsr A-PCP didomain reveals a dynamic entitity. (a) The 
crystal structure of CARsr A-PCP in the adenylation state. (b) The thiolation state crystal 
strucure, color coded as in Figure 1. (c,d) A detailed view of the interactions established 
between the AMP-bound Acore and the Asub domain for the adenylation state (c) and 
thiolation state (d). 
 
Fig. 3. Structure of CAR reductase and PCP-R regions. (a) An overlay of both CARmm 
and CARsr reductase domains (dark and light green, respectively) with the related MxaA 
reductase domain (grey). The position of the smaller substrate binding domain is 
distinct for the CAR R domains, suggesting the possibility of domain motion as indicated 
by the arrow. (b) An overlay of the active site of CARmm reductase in the on (light green 
carbons) and off (grey carbons) active site conformations. (c,d) The structures of 
unmodified (c) and phosphopantetheine-modified (d) CARsr PCP–R didomain 
fragments, color coded as in Figure 1. (e) A detailed view of the CARsr 
phosphopantetheine binding pocket.  
 
Fig 4. Modeling of the full-length CAR structure.  (a) A model for the CARsr 
acetylation/reduction state, derived from an overlay of the PCP domains of the A–PCP 
(acetylation state) and PCP–R crystal structures, color coded as in Figure 1. (b) A model 
for the CAR thiolation state, derived by superimposition of the A–PCP thiolation state 
structure with the PCP–R SAXS models. Multiple conformations of the reductase domain 
are shown as derived from the SAXS profile for the isolated PCP–R didomain 
(Supplementary Fig. 7). (c) The ensemble of structures that can account for the 
observed SAXS profile of the full length enzyme (Supplementary Fig. 8). While the 
individual models used can account for the observed SAXS profile of the full-length 
enzyme, this does not mean these are necessarily highly populated conformations.  
 
Fig 5. A dynamic model for CAR. A schematic representation of the conformational 
rearrangements during the CAR enzymatic cycle. We propose the CAR dynamic 
equilibrium randomly explores various conformations, some relevant with respect to 
catalysis, others for ligand exchange, and is not poised towards either the 
adenylation/reduction or thiolation conformations. In addition to the large scale 
reorientation of the individual domains, the reductase component displays a relatively 
small scale conformational equilibrium that affects the active site region and is 
inherently poised towards the inactive state. Docking of the phosphopantetheine group 
in the reductase active site leads to substrate-induced active site remodeling and 
activation. It is possible that reduction might occur simultaneously with activation of the 
next substrate molecule in the adenylation domain. 
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Online methods 
 
Cloning and molecular biology 
All FL-CAR enzymes were cloned into pET28b using Infusion® HD Cloning technology 
to give a N-terminal His-tag. The experiment was designed in silico using the SnapGene 
software and pET28-b vector linearized using the restrictions sites NdeI and EcoRI. 
Individual CAR domains and their boundaries were identified with the software MOTIF 
scan and PSI-blast searches. Sequence alignments with known NRPS modules were used 
to select the final domain boundaries for cloning. Truncated CAR constructs containing 
just N-terminal domains were designed and cloned with a N-terminal His-tag and C-
terminal CAR domains with a C-terminal His-tag. Individual CAR domains were cloned 
using the same protocol adopted for FL-CARs accept NcoI was used instead of NdeI for 
N-terminal constructs. For CARsr constructs, DNA corresponding to CARsr Full-length 
(FL), Adenylation (A), Adenylation-PCP (A-PCP), PCP-Reductase (PCP-R) and Reductase 
(R) was amplified by PCR from the CARsr gene. PCR products were cloned into the 
Ligation independent cloning site of pNIC28a-Bsa4 vector using the ligation-
independent method (Infusion HD, Clontech). These constructs have N-terminal His-tag 
and Tobacco Etched Virus (TEV) protease cleavage site followed by amino acid 
sequence. Sequence of all the constructs were verified by DNA sequencing (Eurofins). 
Point mutations in CARsr were introduced by Q5® site-directed mutagenesis kit (NEB).  
 
 
Protein expression and purification 
Expression and purification of CARmm/ni and sr enzymes and individual (di)domain. E. 
coli BL21 (DE3) were transformed with one or two plasmids: a pET28-b containing FL-
CAR or containing the individual CAR domains, and where modification with 
phoshopantetheine was required (for activity studies and/or crystallography), a second 
vector, pCDF1b-Sfp, containing the gene for the expression of Sfp: phosphopantetheine 
transferase from Bacillus subtilis. A single colony was then used to inoculate 5 mL of LB 
medium containing 50 μg/mL streptomycin (only where the pCDF1b-Sfp vector was 
present) and kanamycin, and grown overnight, shaking at 37 °C. For CARmm/ni  
expression, the inoculum was transferred and grown to mid-log phase in 2 L baffled 
flasks, containing TB medium, induced with 0.4 mM IPTG and shaken for 24 hours at 20 
°C. Proteins were purified to homology using Nis60 Ni resin (Clontech) followed by size 
exclusion chromatography with a prep grade 26/60 Hi-load Superdex S200 purification 
column. Final samples were eluted in 25 mM Tris pH 8.0 and 150 mM NaCL.  
 
For expression and purification of the CARsr constructs (FL, A, A-PCP, PCP-R and R), 
cultures were incubated at 37 °C to an optical density (OD600) between 0.6-0.8, and 
protein expression was induced with 0.1 mM IPTG at 20 °C for 16 h. Cells were 
harvested by centrifugation and stored in -80 °C until further use. For purification, cells 
were re-suspended in Ni-binding buffer (20 mM HEPES pH 7.4, 0.5 M NaCl, 10 mM 
Imidazole) supplemented with EDTA-free protease inhibitor cocktail tablet (Sigma). The 
cells were lysed by cell-disruptor followed by centrifugation at 48,000 ×g for 1h. Cleared 
supernatant was loaded on to equilibrated Ni-NTA agarose resin (Qiagen) and final 
elution was done with 250 mM imidazole. Affinity His-tag was removed by TEV protease 
cleavage at 4 °C. Cleaved protein was passed back over the Ni-NTA agarose beads and 
flow-through was collected. Cleaved protein was further cleaned by ion-exchange 
chromatography using the ResQ (6ml) column (GE healthcare). Protein was eluted in a 
linear gradient of NaCl (0-1 M). Protein-containing fractions were pooled together and 
concentrated up to ~10 mg/ml with 10 K MWCO (Vivaspin) filtration unit.  
 
In vitro modification of CARsr PCP-R by Sfp 
CARsr PCP-R didomain was modified by promiscuous phosphopantetheinyl transferase 
Sfp according to the method described previously [33]. In brief, 0.1 M purified Sfp was 
mixed with 5 M of PCP-R protein and 5 M benzoyl-CoA (Sigma) in 50 mM HEPES pH 
7.5 and 10 mM MgCl2 in total 100 l volume. This reaction mixture was incubated at 
room temperature minimum for 2h. In order to remove Sfp, the mixture was separated 
using gel-filtration. 
 
Screening for CAR activity  
The activity of FL-CAR towards a range of carboxylic acids was tested by following the 
reduction of NADPH at 340 nm over 1 min. Measurement were performed using a Tecan 
infinite M200 pro 96 wells plate spectrophotometer fitted with an injector. Seven 
alternative CARs were tested using the following conditions: 0.15 mM NADPH 1 mM 
ATP, 10 mM MgCl2, 5 mM substrate, 2.5% DMSO (for substrate solubility) in 50 mM Tris-
HCl pH 7.5, room temperature. 
The reactions were tested in 96 well plates using a total volume of 200 μL per well. The 
amount of enzyme used for each reaction was constant (5 μL). The enzyme was pre-
pipetted in the wells and the rest of the reaction mix injected in each well just before the 
measurement started. Each measurement ran for 1 minute and the slope was then 
calculated using the Magellan software considering the variation in absorbance between 
3 s and 12 s, over 10 points of measure: this allowed for elimination of the mixing effect 
observed occasionally just after injection and allowed for measurement of the activity of 
the enzymes in the linear range. All measurements were corrected with an appropriate 
blank. All measurements were generally repeated in quadruplicate and at least in 
triplicate for each sample. The substrates tested are reported in Supplementary Fig. 1.  
Activity assays for individual N-terminal domains were carried out with the 
commercially available EnzChek assay kit and 1 mM ATP, 10 mM MgCl2, 5 mM substrate 
and 50 mM Tris-HCl pH 7.5. Reactions were monitored for the conversion of 2-amino-6-
mercapto-7-methylpurine riboside (MESG) by purine nucleoside phosphorylase (PNP) 
to ribose 1-phosphate and 2-amino-6-mercapto-7-methyl- purine at 360 nm over 15 
minutes.  
Substrate dependent NADPH oxidation activity of CARsr (FL, ACP-R, R, A+ACP-R as well 
as variants) was monitored by NADPH consumption at 340 nm. Assays were carried out 
in 50 mM Tris-Cl pH 7.5, 150 mM NaCl, 10 mM MgCl2, 1 mM ATP, 1 mM NADPH, 5mM of 
respectively benzoic acid, benzoyl-CoA or thiobenzoate. The effect of R-pantetheine, 
decanethiol and pentanethiol on substrate dependent NADPH oxidation was assessed by 
addition to 2mM final concentration of these compounds.  Activity assays using 
benzaldehyde as a substrate were carried out using a similar protocol, but with 15 mM 
of benzaldehyde as final concentration.  
Crystallization and Structure determination 
Crystals of A domain CARni (30mg/ml) were obtained using the sitting-drop vapour-
diffusion and grew within 7 days at 4 °C in 0.12 M ethylene glycols 0.1 M Tris-Bicine pH 
8.5 30% glycerol/PEG 4K. The structure of A domain of CARni was solved by single-
wavelength anomalous (SAD) method. Experimental phases were obtained by soaking 
crystals with 1M KI for 30 s before flash freezing in liquid N2. A SAD diffraction data set 
was collected from a single flash-cooled crystal at Diamond light source (beamline IO4) 
and reflections merged and scaled with Xia2 [34]. The A domain CARni was solved using 
the SHELX C/D/E software package [35]. A total of 8 iodides were located (SHELX C), 
with sufficient phasing power to generate a heavy atom substructure (SHELX D), for 
phasing and density modification with SHELX E. Initial model building was done with 
ARP/wARP followed by iterative cycles of manual model building and refinement in 
COOT [36] and with Phenix.refine [37] respectively. Structure of the A domain CARni in 
complex with benzoic acid was obtained by soaking the crystals in a solution of mother 
liquor supplemented with 0.1 M benzoic acid prior to flash-cooling.  
 
Crystals of R domain CARmm (20 mg/ml) were obtained by sitting-drop vapour 
diffusion in 0.2 M Na citrate tribasic dehydrate, 0.1 M Bis-tris propane pH 6.5 and 20% 
PEG3350. Co-crystals of CARmm R domain with NADPH4 were obtained in 0.2 M sodium 
sulphate, 0.1 M Bis-Tris-propane pH 6.5, 20% PEG3350 (SG C2221) and 0.2 M 
ammonium tartrate dibasic, 20% PEG3350 (SG P21). Crystals were cryo-protected either 
in PFO oil (Hampton research) or PEG200 before flash freezing in liquid nitrogen. 
Structure of Red CARmm was solved by molecular replacement using Phaser [35] and 
the NRP terminal reductase domain from Mycobacterium smegmatis (PDB: 4DQV). 
 
Optimized crystals of CARsr A domain (15 mg/ml) were obtained in 0.2 M calcium 
chloride hydrate and 20% PEG3350. CARsr A-PCP (15 mg/ml) (thiolation state) crystals 
were grown in 1.5 M lithium sulphate and 0.1 M HEPES pH 7.5. CARsr A-PCP 
(adenylation/reduction state) crystals were obtained in 0.2 M sodium fluoride, 0.1 M 
Bis-Tris Propane pH 6.5 and 20% PEG3350. CARsr PCP-R crystals were obtained in the 
condition 0.1 M sodium malonate dibasic monohydrate, 0.1 M HEPES pH 7.0, 0.5% 
Jeffamine ED-2003. Sfp treated CARsr PCP-R crystals were obtained in 0.1 M carboxylic 
acids 0.1M, 0.1M Imidazole/MES monohydrate pH 6.5, 50% ethylene glycol/PEG8K of 
the Morpheus screen (Molecular Dimension, UK).   
 
All the datasets were integrated and scaled using the program XDS [38]. Structure 
determination of adenylation domain was done by molecular replacement using the 
CARni A domain as a search model. Structures of A-PCP didomain were solved by 
molecular replacement [39], using the A domain CARsr structure as a search model. 
Iterative cycles of manual building in Coot [36] and refinement in Refmac [40] were 
used to complete the models. Iterative cycles of manual building in Coot and refinement 
in Refmac were used to complete the models. CARsr R domain structure was solved by 
molecular replacement using the CARmm R domain structure. Structure of CARsr PCP-R 
didomain structure was solved by molecular replacement with refined CARsr R 
structure and carrier protein domain from the CARsr A-PCP structure. 
 
Validation of all the structures were done with Molprobity [41] and PDB-REDO [42] 
were integrated into the iterative rebuild and refinement procedure. The data collection 
and refinement statistics for all structures are summarized in the Supplementary Table 
1.   
 
Small-angle X-ray scattering 
SAXS intensity data, I(q) versus q, (𝑞 = 4𝜋. 𝑠𝑖𝑛2𝜃𝜆) were collected using HPLC SAXS on 
beamline B21 at Diamond Light Source (Didcot, UK). 50 µL of CARsr purified sample was 
loaded onto the Shodex KW-403 size exclusion column mounted on Agilent HPLC and 
the eluent was flowed though the SAXS beam at 0.15 mL/min; the buffer (25 mM Tris-Cl 
pH 8.0, 150 mM NaCl) used as the background was collected after one SEC column 
volume. SAXS data were collected at one-second intervals using a Pilatus 2M detector 
(Dectris, Switzerland) at a distance of 3.9 m and an X-ray wavelength of 1 Å. All the SAXS 
data sets were analyzed by ATSAS [43] and Scatter suite [44]. Crysol [45] and the FoXS 
web server [46,47] were used to assess the fitting of SAXS data with the corresponding 
models. For modeling of CARsr FL, A-PCP and PCP-R proteins, 10,000 independent 
models were generated and analyzed using EOM [48] and the results cross-validated by 
MultiFoxs web server [46,47].  
Multi-angle light scattering and analytical ultracentrifugation 
Purified CARsr protein samples were injected onto a Superdex-200 10/300 GL column 
(GE healthcare) pre-equilibrated with 20 mM HEPES pH 7.4, 150 mM NaCl buffer for the 
MALS analysis. Light scattering intensities of proteins were measured at different angles 
relative to the incident beam and data analysis was performed with ASTRA 6 software 
(Wyatt Technology Corp., CA, USA). Protein fractions from MALS were then used in 
sedimentation velocity experiments using XL-A ultracentrifuge (Beckman Instruments) 
at 50,000 ×rpm (18,200 g) at 20 ˚C and scanning every 90 seconds respectively using a 
wavelength of 280 nm for a total of 200 scans. The sedimentation boundaries were 
analyzed using the program Sedfit v8.7 [49] and hydrodynamic radius (Rh) and frictional 
ratio (f/fo) were calculated with Sednterp [50]. 
 
Stopped-flow experiments 
NADPH was obtained from Sigma-Aldrich and pro-R and pro-S NADP2H were 
synthesized and characterized as described previously [51]. Stopped-flow studies were 
performed on an Applied Photophysics SX20 stopped-flow spectrometer. Experiments 
were conducted in 100 mM potassium phosphate buffer (pH 7.5). Before recording 
stopped-flow measurements CARmm was activated using 10 mM MgCl2, 2 mM α-
methylcinnamic acid and 2 mM ATP at room temperature for 20 min. Reactions were 
initiated by mixing 0.5 µM NADPH (final concentration) with varied concentrations of 
activated enzyme, at 30 °C. For KIE measurements the same concentration of pro-R and 
pro-S NADP2H were mixed with the enzyme. To follow the reductive reaction, NADPH 
was excited at 340 nm, and emission changes were followed using a 400 nm cut-off 
filter.  
 
Steady-state kinetics 
The steady-state turnover of CARmm at different viscosities was determined at 30 °C on 
assay mixtures containing 10 mM MgCl2, 0.1 µM CARmm, 1 mM ATP, 200 µM NADPH 
and 3 mM α-methyl cinnamic acid in 100 mM potassium phosphate buffer (pH 7.5). 
Steady-state NADPH oxidation rates were determined at 340 nm ( 340 = 6.22 mM-1 
cm-1) using Varian Cary 300 Bio UV-Visible Spectrophotometer. Glycerol solutions were 
prepared by weight and viscosity was calculated as described before [52]. ATP, NADPH 
and α-methylcinnamic acid concentrations were varied for respective experiments to 
measure apparent KM values for CARmm, CARni, nmCAR and mnCAR.  
 
CAR biotransformation and HPLC product detection  
Reactions for analysis were carried out on a 500 μL scale in a 2 mL Eppendorf. Typically, 
biotransformation reactions contained 5 mM substrate, 0.25 mg nickel-purified enzyme, 
10 mM ATP, 100 mM MgCl2, 10 mM NADPH in 100 mM Tris.HCl pH 7.5. The reaction 
contained 6.25% v/v DMSO from the addition of the substrate. The reaction was 
incubated at 25°C shaking at 170 rpm for 24 hr. Reactions were extracted by addition of 
100 μL HPLC grade acetonitrile to 100 μL of sample, vortexed, centrifuged and filtered, 
samples were then analysed by HPLC. Samples to be analysed by HPLC and product 
conversions calculated were extracted with acetonitrile containing the 1 mg/mL 1-
phenylethanol as an external standard.  
 
Reverse phase HPLC was carried out using an Agilent 1200 Series system equipped with 
a G1322A degasser, G1311A Quaternary pump, G1329A standard autosampler (ALS) 
and a G1315B diode-array detector (DAD). All HPLC analysis was carried out using a 
phenomenex® HyperClone™ 5 μm ODS C18 120 Å LC column (250 × 4.6 mm). Samples 
were analysed using a gradient method between two solvents, Solvent A the aqueous 
phase, HPLC grade H2O (0.1% TFA) and solvent B LC-MS grade acetonitrile (0.1% TFA). 
The initial mobile phase was 90% A, 10% B, a linear gradient was then employed over 
30 min to a ratio of 30% A, 70% B, this was then returned to 90% A, 10% B over a 
further 10 min. Samples were run at room temperature, a sample injection volume of 10 
μL, detection wavelength of 215 nm, and a flow rate of 1 mL/min were used. 
Conversions of products as a percentage were calculated using peak area integrations of 
products in ratio to the external standard 1-phenylethanol.   
 
In order to calculate product conversion a calibration curve was performed for 
benzaldehyde and benzyl alcohol using the external standard 1-phenylethanol. 
Standards containing 1 mg/mL 1-phenylethanol and either 0.125 mg/mL, 0.25 mg/mL, 
0.5 mg/mL and 1 mg/mL of benzaldehyde or benzyl alcohol were analysed by HPLC 
using the method described. Conversions were calculated using the linear relationship 
determined between the known concentration of product standards and the ratio of 
peak areas of these products standards and the external standard.  
 
HPLC grade water was purchased from Romil Ltd (Cambridge, UK), Acetonitrile 
CHROMASOLV™ LC-MS was purchased from Honeywell Riedel-de Haën™ (Bucharest, 
Romania). Benzoic acid, benzaldehyde, benzyl alcohol, 1-phenylethanol, DMSO and 
trifluoroacetic acid were purchased from Sigma (Dorset, UK). 
 
Data availability 
Coordinates and associated structure factors have been deposited with the PDB under 
accession codes 5MSC, 5MSD, 5MST, 5MSS, 5MSW, 5MSR, 5MSP, 5MSV, 5MSU and 5MSO. 
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